Supportive Care in Cancer · 2015 · 101 citations · 15 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyChemotherapyBreast Cancer PharmacotherapyCancer ImmunotherapyChemotherapy Toxicity ManagementCombination ChemotherapyCytotoxic ChemotherapyImmunotherapy For Breast CancerBreast Cancer ChemotherapyChemotherapy Toxicity PreventionCyclophosphamide-based TherapyFebrile Neutropenia TreatmentGranulocyte Colony-stimulating Factor AdministrationGranulocyte Colony-stimulating Factor MobilizationGranulocyte-macrophage Colony-stimulating Factor MobilizationPlacebo Comparators
PURPOSE: Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and cyclophosphamide (TC) chemotherapy. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to determine the efficacy of pegfilgrastim in reducing the risk of FN in early-stage breast cancer patients. A total of 351 women (177 in the pegfilgrastim group and 174 in the placebo group) between 20 and 69 years of age with stage I-III invasive breast carcinoma who were to receive TC chemotherapy (docetaxel 75 mg/m(2) and cyclophosphamide 600 mg/m(2) every 3 weeks) as either neoadjuvant or adjuvant therapy were enrolled; 346 of these patients were treated with either pegfilgrastim (n = 173) or placebo (n = 173). RESULTS: The incidence of FN was significantly lower in the pegfilgrastim group than in the placebo group (1.2 vs. 68.8 %, respectively; P < 0.001). In addition, patients in the pegfilgrastim group required less hospitalization and antibiotics for FN. Most adverse events were consistent with those expected for breast cancer subjects receiving TC chemotherapy. CONCLUSIONS: Pegfilgrastim is safe and significantly reduces the incidence of FN in breast cancer patients.
15
Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 540 citations · Full text
Medicine, Oncology, Pharmacology +17
Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll et al. · Journal of Clinical Oncology · 2005 · 481 citations · Full text
Medicine, Oncology, Pharmacology +16
David R. Gandara, Tomoya Kawaguchi, John Crowley et al. · Journal of Clinical Oncology · 2009 · 214 citations · Full text
Medicine, Oncology, Pharmacology +17